No blended recommendations
A label and a professional guideline may differ. A different formulation or indication may only appear to conflict. Read the complete stored source, its date, renal measure, population and qualifications. These new interpretations remain pending independent clinical review.
Find a review question
Use drug/source terms only, never patient identifiers. Filters are in the URL. No JavaScript is required. CSV includes all matches, not just this page.
13 matching checks; page 1 of 2.
Guideline difference | Added v4.9
Has the expert avoidance recommendation been distinguished from the qualitative label?
Baclofen - OZOBAX oral solution
The OZOBAX label gives no numerical cutoff. Wolf et al. recommend reduction in moderate dysfunction and avoidance in severe dysfunction or renal replacement therapy, based on case-based expert interpretation.
What to checkAttribute the literature recommendation and evidence limits. Do not invent a reduction percentage or describe it as a product-specific trial.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Guideline difference | Added v4.5
Is the proposed schedule from standalone EMTRIVA labeling or NIH guidance?
Emtricitabine (Emtriva)
The standalone capsule/solution label reduces dosing at selected bands where NIH uses no adjustment. NIH footnote b explains its incorporation of some fixed-dose-product guidance.
What to checkChoose and document one applicable institutional/specialist approach. Do not average schedules or silently relabel the NIH approach as the standalone product label.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Guideline difference | Added v4.5
Is a limited-evidence expert exception being mistaken for standard label dosing?
Epzicom (abacavir/lamivudine)
The selected label does not recommend the fixed-dose combination below CrCl 30. NIH describes some panel members retaining full-dose lamivudine there but explicitly states that evidence is insufficient.
What to checkPreserve the evidence qualification and obtain HIV-specialist or institutional adjudication. Do not present that exception as a new label-approved dose.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Guideline difference | Added v4.7
Are all stability, renal-function and duration qualifications met?
Linezolid
UCSF describes an optional expert reduction for selected stable patients receiving a prolonged course, rather than a universal renal reduction. Its dialysis table remains separately stated.
What to checkDocument the source and qualifying clinical context; involve infectious diseases and consider drug-level monitoring. Do not apply the expert exception indiscriminately.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Guideline difference | Added v4.7
Does the avoid-use warning limit use despite a printed renal dose?
Lofexidine - LUCEMYRA
The retrieved 2026 official label retains both a renal dosage table and an avoid-use warning for chronic renal failure. This is an unresolved within-label applicability tension, not evidence that either passage can be discarded.
What to checkDo not use the table as automatic eligibility. Review the full warning, vital signs, ECG and specialist assessment; the RX mirror is not independent corroboration.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Guideline difference | Added v4.7
Has the loading day and daily total been checked against the chosen source?
Minocycline - MINOCIN injection
The injection label limits total daily dosing in renal impairment. UCSF describes a loading dose and selected higher-dose practice without a renal reduction. A loading day or high-dose regimen is not silently reconciled with that ceiling.
What to checkKeep the label and institutional pathways separate; obtain stewardship adjudication and retain BUN, creatinine and magnesium-vehicle monitoring.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Guideline difference | Added v4.8
Have the renal-category definitions and neurotoxicity limits been reconciled?
Nelarabine - ARRANON injection
The label cannot recommend a dose below CrCl 50. eviQ describes PK-based no adjustment in mild/moderate impairment but gives no numerical renal bands; scope alignment remains unresolved.
What to checkObtain oncology/pharmacy adjudication without assigning eviQ an invented cutoff; retain the neurotoxicity stopping rule.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Guideline difference | Added v4.8
Which source, renal measure and clinical exception actually apply?
Nitrofurantoin
The label restriction, UCSF limited-data position and UK short-course exception differ in renal measure, setting and qualifications. UCSF is not an endorsement down to CrCl 30.
What to checkDocument jurisdiction and infection scope; preserve the UK multidrug-resistant lower-UTI and benefit-risk qualifications. Do not convert eGFR thresholds into CrCl cutoffs.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Guideline difference | Added v4.9
Has the severe-renal discrepancy been resolved with the controlling official product label?
Oteseconazole - VIVJOA capsules
The RX mirror permits severe impairment; retrieved DailyMed and manufacturer safety wording do not. The mirror prints April 2024; DailyMed has a January 2026 header but an April 2022 PI revision.
What to checkHold the more permissive RX instruction for exact-label reconciliation. Do not treat header/retrieval dates as new label revisions or prescribe from the disputed extract.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Guideline difference | Added v5.0
Has the discrepancy been resolved with an exact controlling label rather than a date assumption?
Oteseconazole - VIVJOA capsules
The current RX recheck remains permissive in severe impairment; the retrieved DailyMed renal section remains restrictive. Header and retrieval dates do not establish a new prescribing-information revision.
What to checkContinue holding the disputed RX instruction. This release does not claim exact controlling-label reconciliation.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Before using a source
Confirm exact product and route, indication, age/weight, renal estimate and units, changing renal function, dialysis modality and timing, interacting medicines, monitoring, and the applicable institution's review. A successful page retrieval or a source-count badge establishes none of these on its own.
Clinician interpretation guideReturn to top